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Abstract
Monocarboxylate transporter 8 (MCT8) is a well-established thyroid hormone (TH) transporter. In humans, MCT8 mutations
result in changes in circulating TH concentrations and X-linked severe global neurodevelopmental delay. MCT8 is expressed
in the human placenta throughout gestation, with increased expression in trophoblast cells from growth-restricted
pregnancies. We postulate that MCT8 plays an important role in placental development and transplacental TH transport. We
investigated the effect of altering MCT8 expression in human trophoblast in vitro and in a Mct8 knockout mouse model.
Silencing of endogenous MCT8 reduced T3 uptake into human extravillous trophoblast-like cells (SGHPL-4; 40%, P,0.05)
and primary cytotrophoblast (15%, P,0.05). MCT8 over-expression transiently increased T3 uptake (SGHPL-4:30%, P,0.05;
cytotrophoblast: 15%, P,0.05). Silencing MCT8 did not significantly affect SGHPL-4 invasion, but with MCT8 over-expression
T3 treatment promoted invasion compared with no T3 (3.3-fold; P,0.05). Furthermore, MCT8 silencing increased
cytotrophoblast viability (,20%, P,0.05) and MCT8 over-expression reduced cytotrophoblast viability independently of T3
(,20%, P,0.05). In vivo, Mct8 knockout reduced fetal:placental weight ratios compared with wild-type controls at
gestational day 18 (25%, P,0.05) but absolute fetal and placental weights were not significantly different. The volume
fraction of the labyrinthine zone of the placenta, which facilitates maternal-fetal exchange, was reduced in Mct8 knockout
placentae (10%, P,0.05). However, there was no effect on mouse placental cell proliferation in vivo. We conclude that MCT8
makes a significant contribution to T3 uptake into human trophoblast cells and has a role in modulating human trophoblast
cell invasion and viability. In mice, Mct8 knockout has subtle effects upon fetoplacental growth and does not significantly
affect placental cell viability probably due to compensatory mechanisms in vivo.
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Introduction
The importance of maternal thyroid hormone (TH) availability
to normal fetoplacental development is highlighted by the
association of untreated maternal thyroid dysfunction with
pregnancy complications, including miscarriage, pre-eclampsia,
intrauterine growth restriction (IUGR) and stillbirth [1,2,3,4].
These complications are often characterized by malplacentation or
uteroplacental insufficiency. Such associations are therefore
postulated to occur through the direct effects of maternal TH
upon placental development, as well as through alterations in the
transplacental passage of TH from the mother to the fetus.
The human placenta is thought to be TH-responsive [5], as
evidenced by the expression of the full complement of proteins that
are required to mediate TH action from early gestation onwards.
The entry of maternal TH into trophoblast, as well as its passage
across the placenta to the developing fetus, is facilitated by several
plasma membrane proteins that can transport THs, including the
monocarboxylate transporter 8 (MCT8) [6,7]. From early
gestation the human placenta also expresses TH receptor isoforms
(TRa1, TRb1), which are nuclear transcription factors that can
bind to the active TH ligand, tri-iodothyronine (T3), to regulate
transcription of TH-responsive genes [8,9]. Furthermore the
human placenta demonstrates pre-receptor regulation by deiodi-
nase enzymes type 2 (D2; converts thyroxine [T4] to T3) and type
3 (D3; inactivates T4 and T3) [10] with the latter playing a critical
role in regulating the transplacental passage of TH [11].
The SLC16A2 gene located on the X chromosome encodes the
MCT8 protein, a 63 kDa transmembrane protein, which is a well-
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established TH transporter. Injection of rat Mct8 mRNA into
Xenopus oocytes resulted in a 10-fold increase in T4 and T3 uptake
[12], whilst the transfection of human MCT8 cDNA into COS1
and JEG3 cells, which have little or no endogenous MCT8, more
than doubled the uptake of T3 [13]. MCT8 has a broad tissue
distribution, with the placenta being one of the tissues showing a
relative abundance of MCT8 expression [14,15]. There has been
much interest in this gene since the discovery that human MCT8
mutations result in X-linked severe global neurodevelopmental
delay associated with low circulating T4, high T3 and normal or
slightly elevated thyroid stimulating hormone (TSH)
[16,17,18,19]. Although it is widely believed that impairments in
MCT8 function within the fetal brain, liver and other organs result
in this phenotype [20], it is still unknown if disrupted transpla-
cental passage of TH or impaired placental development also
contribute to the phenotype.
Recently, two genotypically different Mct8 knockout mice
models have been developed [21,22]. Both models demonstrate
changes in serum TH concentrations similar to that observed in
patients affected by MCT8 mutations. Unlike human patients,
Mct8 knockout mice do not exhibit any overt neurodevelopmental
disorders nor a decline in postnatal growth. There is also no
difference in fertility or reproductive function. However, the effect
of Mct8 deficiency on fetoplacental growth and development has
not been investigated so far.
We have previously reported that MCT8 is expressed in the
human placenta from six weeks of gestation with increased
expression with advancing gestational age [6,23]. Within the
human placenta MCT8 protein is localized to villous cytotropho-
blast, syncytiotrophoblast (a layer formed by differentiating
cytotrophoblast cells fusing together that constitutes the primary
physical barrier that controls transplacental transport) and
extravillous trophoblast (EVT; cells that invade into the decid-
ualized maternal endometrium and spiral arteries to facilitate
adequate maternal blood supply into the placental bed) [23].
MCT8 protein expression in the human placenta, and specifically
in primary villous cytotrophoblast, is significantly increased in
pregnancies complicated by IUGR compared with gestationally-
matched appropriately grown controls [6,23,24]. In vitro experi-
ments have demonstrated that T3 increases the invasive potential
of primary EVT [25] and suppresses their apoptosis [26], and
could promote epidermal growth factor production by first
trimester placental explants [27].
We hypothesized that MCT8 could influence placental devel-
opment by regulating TH uptake and hence the intracellular
availability of T3, which alters human trophoblast cell function
and viability. To investigate this hypothesis, MCT8 expression was
silenced or over-expressed in two human trophoblast cell types:
EVT and cytotrophoblast cells. In addition, the Mct8 knockout
mouse model was used to investigate the role of MCT8 in
fetoplacental growth and placental morphology in vivo.
Materials and Methods
In vitro Experiments
Ethical approval. Human samples were collected with
informed written consent and with the approval of the South
Birmingham research ethics committee and the Research and
Development office of the Birmingham Women’s NHS Founda-
tion Trust according to the Declaration of Helsinki.
Sample collection. Human placentae from uncomplicated
pregnancies were collected following elective pregnancy termina-
tion (n= 5; 11 weeks of gestation) or elective caesarean section
(n= 13; median gestational age 39 weeks, range 38+3–39+2). The
fetuses were not known to have abnormal karyotypes and none of
the pregnancies was complicated by thyroid disorders.
Cell isolation and culture. To investigate the role of MCT8
in EVT, primary EVT cells were isolated from first trimester
human placentae, as described previously [28] and cultured on a
thin layer of growth factor-reduced MatrigelH matrix (BD
Biosciences, Erembodegem, Belgium). Primary EVT cells were
used for initial experiments. Due to the limited cell numbers
obtainable from first trimester placenta, a cell line derived from
primary EVT, SGHPL-4 [29], was used for further studies. The
role of MCT8 in villous cytotrophoblast cells was investigated
using primary cytotrophoblast cells isolated from human term
placentae, as described previously [8,24,30,31]. All media were
Figure 1. T3 uptake by SGHPL-4 cells following MCT8 silencing (A) or MCT8 over-expression (B). SGHPL-4 cells were incubated for 0 to
30 minutes with [125I]-T3. The amount of intracellular radioactivity was quantified and expressed as a percentage of the total radioactivity added.
Points represent average of three experiments 6SEM. Within each experiment, each condition was performed in duplicate. Statistically significant
differences are indicated by a(control siRNA vs MCT8 siRNA) b(VO vs MCT8), c(VO vs MCT8+ CRYM), d(MCT8+ CRYM vs CRYM) and e(MCT8 vs MCT8+
CRYM); *P,0.05, **P,0.01 and ***P,0.001.
doi:10.1371/journal.pone.0065402.g001
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supplemented with either 10% (v/v) fetal calf serum (FCS;
Invitrogen, Paisley, UK) or with 10% (v/v) charcoal-stripped fetal
calf serum (SFCS; First Link, Birmingham, UK), which is devoid
of THs, for experiments that involved T3 treatment.
Silencing and over-expression of MCT8
expression. AmaxaH electroporation (Lonza, Basel, Switzer-
land) was used for the delivery of small interfering RNA (siRNA)
or plasmid DNA into cells as per manufacturer’s instructions. For
SGHPL-4 cells, solution V and program X-001 were used. The kit
for primary epithelial cells and program T-013 was used for
cytotrophoblast cells. For the suppression of endogenous MCT8
expression (MCT8 silencing), cells were transfected with MCT8-
specific siRNA (final concentration 100 nM; sense sequence:
GCCUGCGCUACUUCACCUAtt) or with a non-targeting
control (sense sequence: GGGCCACAGUUUCAGCUUCtt;
Ambion, Warrington, UK). For transient up-regulation of
MCT8 expression (MCT8 over-expression) the cells were trans-
fected with plasmid DNA (1 mg) (pcDNA3.1+; Invitrogen)
containing the cDNA for human wild-type MCT8 with a C-
terminal hemagglutinin (HA) tag [32]. PcDNA3.1+ plasmid
lacking the MCT8 cDNA was used as a vector only (VO) control.
Cell recovery, assessed by cell counting under a microscope 24
hours post-transfection, was approximately 80% for SGHPL-4
and 50% for cytotrophoblast (data not shown).
Successful silencing of endogenous MCT8 and overexpression
of HA-tagged MCT8 were confirmed by TaqMan PCR, flow
cytometry and western blotting, as previously described [24]. In
SGHPL-4 cells, transfection with MCT8 siRNA resulted in a 70%
reduction in MCT8 mRNA (P,0.001) with undetectable MCT8
protein in lysates from cells transfected with MCT8 siRNA
(Figures S1A–B). Over-expression of MCT8 protein 72 hours post-
transfection assessed by flow cytometry showed that 41% of
SGHPL-4s were expressing the transfected MCT8 protein and
increased protein expression was also confirmed by western
Figure 2. T3 uptake in primary cytotrophoblast cells following MCT8 silencing (A,C) or MCT8 over-expression (B,D). A and B: T3
uptake time course from one representative experiment. Cytotrophoblast cells were incubated for 0 to 30 minutes with [125I]-T3. The amount of
intracellular radioactivity was quantified and expressed as a percentage of the total radioactivity added. C and D: Relative T3 uptake following
incubation for 10 minutes with [125I]-T3. Bars represent average of four experiments +SEM. Within each experiment, each condition was performed in
duplicate. The mean uptake for the control within each experiment has been assigned the value of 100%. Statisticallysignificant differences are
indicated by *P,0.05 and **P,0.01.
doi:10.1371/journal.pone.0065402.g002
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Figure 3. Effect of MCT8 and T3 on EVT invasiveness and motility. A: Representative pictures of first trimester primary EVT cells that invaded
through MatrigelH (arrows) following treatment with 0 or 10 nM T3. The cells were stained with Mayer’s hematoxylin and eosin. B: Index of invasion
by first trimester primary EVT following treatment with 0 or 10 nM T3. Bars represent average of six experiments+SEM. Within each experiment, each
condition was performed in triplicate and the results normalized to the mean value for the controls. C and D: Invasion of the EVT-like SGHPL-4 cells
through MatrigelH following silencing of endogenous MCT8 expression (C) or over-expression of MCT8 (D) and treatment with 0 or 10 nM T3. The
number of invading cells was normalized to the average number of invading cells in the control groups that were transfected with control siRNA or
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blotting (Figure S1C–D). In cytotrophoblast cells, transfection with
MCT8 siRNA resulted in 90% reduction in MCT8 mRNA
expression (P,0.001) and undetectable MCT8 protein (Figure
S2A–B). Over-expression of MCT8 protein assessed by flow
cytometry showed that 28% of cytotrophoblast cells were
expressing the transfected MCT8 protein and this was also
confirmed by western blotting (Figure S2C–D).
T3 uptake assays. Following silencing or over-expression of
MCT8 expression the cells were cultured for 72 hours in duplicate
in 10% FCS-supplemented medium. The cells were incubated
with serum-free medium supplemented with 1 nM T3 containing
approximately 26105 cpm of [125I]-T3 (Perkin Elmer, Massachu-
setts, USA) and [125I]-T3 uptake was measured, as previously
described [24]. In addition, SGHPL-4 cells were also transfected
with plasmid containing the m-crystallin cDNA (CRYM; Im-
agenes; Berlin, Germany), on its own or co-transfected with
MCT8. Since CRYM binds T3 intracellularly [33,34], co-
transfection with this protein was used to increase the intracellular
T3-binding capacity of the cells and thus decrease the rate of T3
efflux.
Cell invasion. Following isolation (primary EVT) or AmaxaH
electroporation (SGHPL-4), cells were cultured in cell culture
inserts [8 mm membrane pore size] coated with 10 ml of growth
factor-reduced MatrigelH matrix (BD Biosciences). Cells were
treated with 0 or 10 nM T3 and cell invasion through MatrigelH
was assessed 48 or 72 hours later by counting all the invaded cells
visualized with Mayer’s hematoxylin and eosin (H&E). The
invasion index was determined and expressed as the ratio of
invaded cells in the experimental group relative to that in the
respective control group (EVT: cells treated with 0 nM T3;
SGHPL-4: cells transfected with control siRNA or VO and treated
with 0 nM T3).
Cell motility. The effect of MCT8 silencing or over-
expression on SGHPL-4 motility was assessed. To identify cells
that were successfully transfected with MCT8, a plasmid
containing cDNA encoding a fusion protein for hMCT8 and
GFP was constructed (MCT8-GFP). PcDNA3.1+ plasmid encod-
ing GFP was used as control (GFP). Transfection of SGHPL-4
with MCT8-HA or MCT8-GFP resulted in a similar increase in
T3 uptake, which was 30% (67) and 30% (613) respectively
following incubation with [125I]-T3 for 10 minutes. Following
electroporation the cells were allowed to adhere overnight in 10%
(v/v) FCS-supplemented media followed by a 4-hour incubation in
media supplemented with 10% (v/v) SFCS before treatment with
0 or 10 nM T3. Cell motility was assessed by time-lapse
microscopy (TLM) over 20 hours, as described previously [29].
Twenty cells per field of view were chosen at random and the
distance moved was measured using ImageJ (U. S. National
Institutes of Health, Bethesda, MD, USA). Within each exper-
iment the results were normalized to the values obtained from the
control groups (as defined above).
Cell survival and apoptosis. SGHPL-4 cells were allowed
to adhere overnight in 10% (v/v) FCS-supplemented media
followed by a 4-hour incubation in media supplemented with 10%
(v/v) SFCS before treatment with 0 or 10 nM T3 for 48 hours.
Primary term cytotrophoblast cells were cultured in media
supplemented with 10% (v/v) SFCS and from 18 hours post-
isolation were treated with 0 or 10 nM T3 for 48 hours. Cell
number was assessed using the methyltetrazoleum (MTT; Sigma-
Aldrich) colorimetric assay as described previously [8] and by
counting cell nuclei stained with Hoechst 33258 (1:1000; Sigma-
Aldrich). In addition, cell apoptosis was assessed using the
luminescence-based Caspase 3/7 activity assay (Promega, South-
ampton, UK) [32]. The results were normalized to the values
obtained from the control groups (as defined above) within each
experiment. Caspase 3/7 results were also normalized to the MTT
results to correct for cell numbers. In addition, apoptosis in
SGHPL-4 cells was assessed based on changes in cell morphology
seen by TLM as previously described [35].
In vivo Experiments in a Murine Model
Matings, euthanisation and sample collection. Animal
studies were approved by the Animal Welfare Committee of the
Medizinische Hochschule Hannover, Germany. Female Mct8+/2
mice were obtained from Deltagen (San Mateo, CA, USA). All
animals were on a C57/Bl6 background, kept at constant
temperature (22uC) and light cycle (12 hours light, 12 hours dark)
and provided with standard laboratory chow and tap water ad
libitum. Heterozygous female carrier mice (Mct8+/2; n = 26) were
mated with male knockout (Mct82/y) or wild-type mice (Mct8+/y).
Pregnant dams were euthanized at gestational day 14 (E14.5;
n = 17) or at gestational day 18 (E18.5; n = 9) by CO2
administration. Each fetus and placenta was dissected out
separately and weighed. Fetal tails were genotyped by PCR to
determine the sex (SRY gene) and Mct8 status, as previously
described [22]. Fetuses were snap-frozen for analysis of TH
content. Half of each placenta was fixed [4% (w/v) paraformal-
dehyde, 3% (w/v) PIPES, 3% (w/v) PVP40 and 0.02% (w/v)
CaCl2 fixative (pH 7.4)] and paraffin-embedded and the other half
was snap-frozen. Only male Mct8 knockout fetuses and placentae
and male wild-type littermates were used for subsequent exper-
iments.
Mct8 mRNA expression in mouse placenta. To demon-
strate Mct8 expression in the mouse placenta, placentae of wild-
type fetuses at E14.5 (n = 10) and E18.5 (n = 11) were assessed by
TaqMan PCR, as previously described [24], using a commercially
available set of primers and probe (Assay ID: Mm00486204_m1;
Applied Biosystems, Paisley, UK).
Stereo-histological assessment of the placenta. Paraffin-
embedded placentae from E18.5 Mct82/y and Mct8+/y littermates
(n = 6) were entirely sectioned into 7 mm-thick sections. Approx-
imately every tenth section ranging from the centre to the
periphery of the placenta (20 sections per placenta) was stained
with H&E and photographed using a 26 objective lens. The
volume fraction of each region of the mouse placenta [chorionic
plate, labyrinthine zone (Lz), junctional zone, decidua basalis] was
estimated using a grid, as previously described [36]. Absolute
placental volumes were calculated by multiplying the wet placental
weight of each sample by 1.05 (the estimated specific gravity of
placenta) [37].
TH measurements in fetuses. In order to assess maternal
to fetal transfer of TH, the total fetal T4 and T3 content at E14.5
VO and treated with 0 nM T3. Bars represent average of seven (silencing) or six (over-expression) experiments +SEM. Within each experiment, each
condition was performed in duplicate. E and F: Motility of SGHPL-4 cells. Distance moved following MCT8 silencing with siRNA (E) or over-expression
of GFP-tagged MCT8 (F) followed by treatment with 0 or 10 nM T3 for 20 hours. The distance over which cells moved was normalized to the average
distance covered by cells in the control groups that were transfected with control siRNA or GFP only (VO) and treated with 0nM T3. Bars represent
average of three experiments +SEM. Statistically significant differences are indicated by *P,0.05 and **P,0.01. The longer brackets indicate the
overall effect of T3 across all groups by ANOVA and the shorter bracket indicates the significant difference between specific groups assessed by post-
hoc testing.
doi:10.1371/journal.pone.0065402.g003
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(before endogenous fetal TH production) was measured by radio-
immuno assay following TH extraction from tissues, as described
in detail previously [38]. Two to three fetuses of the same genotype
from each litter were pooled together (2–3 per genotype) for the
assay. However, the levels of T4 and T3 were below the detection
limits of the assay in all the samples, both wild-type and Mct8
knockout.
Deiodinase activity assays. The activity of D2 and D3 in
wild-type and Mct8 knockout mouse placentae at E14.5 was
assessed by HPLC, as described previously [39]. From each litter
(n = 7), three placentae of each genotype were pooled together and
processed as a single sample.
Cell proliferation in the mouse placenta. To compare cell
proliferation between wild-type and Mct8 knockout placentae, the
protein expression of Cyclin D1 (1/200; ab16663, Abcam,
Cambridge, UK) in whole placental homogenates (E18.5; n= 6
litters) was assessed by western blotting, as described previously
[24]. To isolate potential changes in trophoblast viability
specifically within the Lz, we counted the number of endothelial
(CD31+ve; stained with antibody ab56299; 1/100; Abcam) and
trophoblast (CD31-ve and identified also by characteristic cell
morphology) cells (all counterstained with Mayer’s hematoxylin) in
five randomly selected fields per placental section (viewed under a
206 objective) from wild-type and knockout placentae (E18.5:
n = 4 litters).
Statistical Analysis
Data were analyzed using MinitabH statistical software (version
15). When comparing two groups, statistical significance was
assessed by paired t-test. For comparisons of more than two
groups, or groups affected by more than one variable, analysis of
variance (ANOVA) was performed using the general linear model.
Tukey all pairwise multiple comparisons post-hoc tests were used
to assess differences between individual groups. Residuals for all
data sets passed the normality test as determined using the
Kolmogorov-Smirnov test.
Results
Effect of MCT8 on T3 Uptake in vitro
To assess the contribution of endogenous MCT8 to TH
transport, we assessed T3 uptake by the EVT-like cell line,
SGHPL-4, and primary term human cytotrophoblast cells
following MCT8 silencing. MCT8 silencing was associated with
a significant reduction in T3 uptake by SGHPL-4 cells (Figure 1A)
with a maximum effect at 10 minutes (40% reduction, P,0.05).
The inhibition of T3 uptake was sustained for the entire 30
minutes of incubation with [125I]-T3. Conversely, MCT8 over-
expression increased T3 uptake by SGHPL-4 cells (Figure 1B;
30%; P,0.05) at 10 minutes. However, at 30 minutes net T3
uptake was similar in MCT8-transfected cells and in VO controls,
presumably because equilibrium was reached by that point. This
supports previous observations indicating that MCT8 could also
facilitate T3 efflux as well as influx. This was confirmed when
SGHPL-4 cells were co-transfected with MCT8 and CRYM, a
cytosolic protein that binds to T3 intracellularly and thus decreases
T3 efflux [33,34]. T3 uptake by SGHPL-4 cells co-transfected
with MCT8 and CRYM was significantly higher than by those
transfected with VO (by 44%), or MCT8 alone (by 44%) or
CRYM alone (by 28%) following 30 minutes of incubation with
[125I]-T3 (P,0.001).
In primary human cytotrophoblast cells T3 uptake over 30
minutes showed a similar pattern to that in SGHPL-4 cells. In
initial time course experiments, MCT8 silencing resulted in
reduced T3 uptake after 10 and 30 minutes of incubation with
[125I]-T3 (Figure 2A), whilst MCT8 over-expression increased T3
uptake by primary cytotrophoblast cells only transiently with the
maximum effect observed at 10 minutes (Figure 2B). To confirm
these observations, further experiments were conducted with
assessments made at 10 minutes (n = 4) showing that MCT8
silencing resulted in a 15% reduction in T3 uptake (Figure 2C,
P,0.05), whilst MCT8 over-expression resulted in a 15% increase
in T3 uptake by cytotrophoblasts (Figure 2D; P,0.01).
Effect of MCT8 on Extravillous Trophoblast Invasion and
Motility in vitro
Treatment of first trimester primary EVT cells with 10 nM T3
resulted in an increase in cell invasion (Figure 3A), with a mean
increase of 3.8-fold compared with untreated cells (Figure 3B,
P,0.05), which is consistent with previous reports [25]. To
investigate the underlying mechanisms of this observation and the
effect of altered MCT8 expression on cell invasion we utilized the
EVT-like cell line, SGHPL-4, as a model of EVT because of the
limited cell numbers obtainable from first trimester placentae.
Treatment of SGHPL-4 cells with 10 nM T3 also resulted in an
overall trend of increased cell invasion (ANOVA effect of T3
P,0.05), suggesting that this is a valid cell model to study T3-
mediated effects on EVT invasion (Figures 3C–D). Even though
silencing MCT8 had no effect on SGHPL-4 invasion through
MatrigelH (Figure 3C), with over-expression of MCT8 T3 induced
a significant pro-invasive effect resulting in a 3.3-fold increase in
cell invasion compared with no T3 (P,0.05), which is more than
the T3-induced effect when cells were transfected with VO
(Figure 3D). In contrast, SGHPL-4 motility was not affected by
changes in MCT8 expression or by T3 treatment (Figures 3E–F).
Effect of MCT8 on Trophoblast Cell Viability in vitro
Silencing endogenous MCT8 in primary term cytotrophoblast
cells increased cell viability as assessed by MTT both in non-
treated (19%, P,0.05) and T3-treated cells after 48 hours (16%,
P,0.05; Figure 4A). Conversely, over-expression of MCT8
decreased cell viability by 17% in the absence of T3 (P,0.05)
and 21% in the presence of T3 (P,0.01) (Figure 4B). This effect
was also confirmed when the number of cell nuclei was counted.
There were more nuclei following MCT8 silencing (ANOVA
effect of MCT8: P,0.05; Figure 4C) and fewer nuclei following
MCT8 over-expression (ANOVA effect of MCT8: P,0.05;
Figure 4D), with similar trends observed in the absence and
presence of T3. However, neither MCT8 silencing nor over-
expression nor T3 treatment affected apoptosis measured by
Caspase 3/7 activity (Figures 4E–F).
Figure 4. Effect of MCT8 silencing (A,C,E) and MCT8 over-expression (B,D,F) on primary term cytotrophoblast cell viability. assessed
by MTT assay (A–B; average of six experiments +SEM, four replicates were performed per condition within each experiment) and by counting nuclei
under a microscope (C–D; average of 3 experiments +SEM; within each experiment 5 fields were counted), and apoptosis by quantification of Caspase
3/7 activity (E–F; average of five experiments +SEM, within each experiment each condition was performed in triplicate). The assays were performed
72 hours following Amaxa electroporation, and 48 hours post-treatment with 0 or 10 nM T3. Results of each sample was normalized to the mean for
cells transfected with control (control siRNA or VO) and treated with 0 nM T3. Caspase activity results were also normalized to the MTT results in order
to correct for cell numbers. Statistically significant differences are indicated by *P,0.05, **P,0.01 and ***P,0.001.
doi:10.1371/journal.pone.0065402.g004
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Figure 5. Effect of MCT8 silencing (A,C,E) and MCT8 over-expression (B,D,F) on the viability of the EVT-like SGHPL-4 cells. assessed
by MTT assay (A–B), and apoptosis by quantification of Caspase 3/7 activity (C–D) and counting the number of apoptotic cells by time lapse
microscopy (E–F). The assays were performed 72 hours following silencing of endogenous MCT8 or transfection with human wild-type MCT8, and 48
hours post-treatment with 0 or 10 nM T3. A and B: The absorbance for each sample was normalized to the average absorbance measured in cells
transfected with control (control siRNA or VO) and treated with 0 nM T3. The bars represent average of five experiments +SEM. Four replicates were
performed per condition within each experiment. C and D: Results were normalized to the MTT results in order to correct for cell numbers. Bars
represent average of three experiments +SEM. Within each experiment, each condition was performed in triplicate. E and F: Bars represent average
of three experiments +SEM. Within each experiment 20 cells were counted per condition.
doi:10.1371/journal.pone.0065402.g005
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In contrast to the observations in primary cytotrophoblast cells,
both silencing and over-expression of MCT8 in SGHPL-4 cells, a
model of EVT, did not affect cell viability as measured by MTT
(Figure 5A–B). Like primary cytotrophoblasts, however, MCT8
also did not affect apoptosis of SGHPL-4 cells as measured by
Caspase 3/7 activity and by morphological assessment by TLM
(Figure 5C–F).
Mct8 Expression in the Mouse Placenta
Messenger RNA encoding Mct8 was demonstrated in the wild-
type mouse placenta at both E14.5 and E18.5. Mct8 mRNA
expression as determined by quantitative RT-PCR was signifi-
cantly increased by 4.7 (61.2) fold (mean6SEM; P,0.01) at
E18.5 compared with E14.5.
Effect of Mct8 on Placental Deiodinase Activities in Mice
D2 activity was undetectable in the mouse placenta. There was
no significant difference in D3 activity between Mct8 wild-type
(177.8637.26 fmol/mg/min; mean6SEM) and knockout
(224.0651.74 fmol/mg/min) placentae at E14.5.
Effect of Mct8 on Mouse Fetal and Placental Weights
In order to find out if lack of Mct8 affects fetal growth or
placental growth we recorded fetal and placental weights at two
gestational ages, E14.5 (which is before the onset of fetal TH
production) and E18.5 (which is after the onset of fetal TH
production and just before delivery). At E14.5 there was no
statistically significant difference in absolute fetal and placental
weights between wild-type fetuses and Mct8 knockout littermates
(Figure 6A–B). However, at E18.5 there was a trend of reduced
fetal weights accompanied by a trend of increased placental
weights with Mct8 knockout compared to wild-type (Figure 6C–
D). This led us to calculate the ratio of fetal:placental weight for
each conceptus, which gives an estimate of the fetal weight that is
supported by each gram of placenta. We found that at E18.5 the
fetal:placental weight ratio was 25% lower in Mct8 knockout
fetuses (P,0.05), but there was no difference at E14.5 (Figure 6E–
F). This is suggestive of placental inefficiency with Mct8 knockout
at E18.5.
Effect of MCT8 on Mouse Placental Morphology
To look for other features indicating placental inefficiency we
assessed whether placental morphology was affected at E18.5. We
performed stereohistological analysis and calculated the volume
fractions and the absolute volumes of each of the regions that
make up the mouse placenta (Figure 7A). The volume fraction of
the Lz relative to the whole placenta was smaller in Mct8 knockout
samples compared to litter-matched wild-type samples (P,0.05)
(Figure 7B). However, there was no difference in the absolute
volume of the Lz between wild-type and knockout placentae
(Figure 7C). No significant differences were observed when
comparing the volume fraction or the absolute volume of the
other regions in the mouse placenta, although there was a general
trend of increased absolute volumes of all regions with Mct8
knock-out, with the Lz showing the least change.
Effect of MCT8 on Cell Proliferation in the Mouse
Placenta
Since in vitro findings suggest that the level of MCT8 expression
affects the viability of human cytotrophoblast cells, we assessed
proliferation in mouse wild-type compared with litter-matched
Mct8 knockout placentae (Figure 8). In whole placental homog-
Figure 6. Absolute fetal (A and C), absolute placental (B and D) weights and fetal to placental weight ratios (E and F) of male wild-
type (+/y) and male Mct8 knockout (2/y) fetuses at gestational day 14 (E14.5; n=17 litters) and 18 (E18.5; n=9 litters). Each dot
represents the weight of individual samples and the lines represent the mean 6SEM for each group. Significant differences between groups are
indicated by *P,0.05.
doi:10.1371/journal.pone.0065402.g006
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Figure 7. Stereohistological analysis of male wild-type (+/y) and male Mct8 knockout (2/y) E18.5 placentae. A: Representative picture
of a placental section (wild-type), stained with hematoxylin and eosin, and photographed using a 26 objective lens. The different regions of the
mouse placenta are annotated: db =decidua basalis, Lz = labyrinthine zone, Jz = junctional zone and c = chorionic plate. B–C: Volume fractions (B) of
the placental regions relative to the whole placenta and absolute volumes (C) of the placental regions in wild-type and litter-matched Mct8 knockout
samples. Six placentae were assessed per genotype. The bars represent the mean 6SEM for each group. Significant differences between groups are
indicated by *P,0.05.
doi:10.1371/journal.pone.0065402.g007
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enates, there was no significant difference in the protein expression
of the proliferation marker, Cyclin D1, at E18.5 (Figure 8A–B). In
light of the findings in human trophoblast and in the mouse
stereology, we sought to isolate possible differences in cell viability
within the Lz. Cell counts of trophoblast and endothelial cells
(distinguished by CD31 staining in conjunction with cell
morphology; Figure 8C) were no different between wild-type
and Mct8 knockout samples at E18.5. The average number of
trophoblast cells per field (6SEM) was 103620 in wild-type and
7969 in Mct8 knockout placentae and the average number of
endothelial cells per field was 162613 and 141628, respectively
(Figure 8D).
Discussion
In this study we have demonstrated that MCT8 makes a
significant contribution to T3 uptake by human trophoblast cells
in vitro. We have also shown that MCT8 promotes the pro-invasive
effect of T3 on the EVT-like cell line, SGHPL-4, whilst it reduces
the viability of primary term human cytotrophoblast cells in a T3-
independent manner in vitro. In vivo data from Mct8 knockout mice
reveal reduced fetal to placental weight ratios, with a smaller
volume fraction of the Lz, where maternal-fetal exchange occurs.
However, significant changes in placental cell growth could not be
demonstrated in vivo.
A significant reduction in net T3 transport following silencing of
endogenous MCT8 in vitro suggests that MCT8 contributes
significantly to net T3 transport by human placental cells. This
is consistent with our observation that MCT8 makes a substantial
contribution to T3 uptake by microvillous membrane vesicles
derived from term syncytiotrophoblast [7]. Human primary term
cytotrophoblast [6,24], primary EVT [6] and SGHPL-4 cells
(unpublished data) express other TH transporters in addition to
MCT8, including MCT10, system-L amino acid transporters
(LAT1, LAT2 and their obligatory heterodimer CD98) and
organic anion transporting polypeptides 1A2 and 4A1. These TH
Figure 8. Proliferation and cell number in male wild-type (+/y) and male Mct8 knockout (2/y) placentae. (A): Changes in the protein
expression of Cyclin D1 (proliferation) were assessed by western blotting. The expression of b-actin was assessed to control for sample loading. A
representative blot is shown for gestational age E18.5. (B): Relative densitometry analysis based on one wild-type and one Mct8 knockout placenta
from each of six litters at E18.5. The bars represent the mean 6SEM. (C): Representative picture demonstrating CD31 immunoreactivity (marker of
endothelial cells represented by brown staining) in the mouse placenta at E18.5. The nuclei were counterstained using hematoxylin. Endothelial cells
are indicated by arrows and trophoblast cells by arrowheads. (D): Number of trophoblast and endothelial cells (counted in five fields per sample
under a 206objective) in the labyrinthine zone of +/y and2/y placentae. One wild-type and one Mct8 knockout placenta from each of four litters at
E18.5 were assessed. The bars represent the mean 6SEM.
doi:10.1371/journal.pone.0065402.g008
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transporters could all facilitate both T3 influx and efflux in the
absence of MCT8. Despite some transporters having a similar
affinity for T3: MCT8 (Km=0.86 mM [40]), system-L
(Km=0.8 mM [41]) and OATP4A1 (Km=0.9 mM [42]), these
other TH transporters cannot completely compensate when
MCT8 is silenced, resulting in reduced T3 retention intracellu-
larly. On the other hand, when MCT8 was over-expressed at
‘‘supraphysiological levels’’, there was an initial increase in T3
uptake, which could not be maintained over a prolonged (30
minute) incubation with [125I]-T3. This suggests that MCT8 over-
expression could facilitate a transient rapid increase in T3 uptake
but not the retention of T3 intracellularly due to T3 efflux taking
place, as confirmed by our studies using co-transfection of MCT8
and CRYM in SGHPL-4 cells. It is probable that MCT8 also
contributed significantly to this T3 efflux, as has been described in
COS1 cells [43]. The relatively smaller magnitude of increase in
T3 uptake in primary cytotrophoblast compared to SGHPL-4 cells
could be partly attributed to the lower transfection efficiency for
cytotrophoblast (28% vs 41%).
These findings raise the possibility that transplacental TH
transport and placental TH content may be impaired in
pregnancies where the fetus is affected by a MCT8 mutation.
To date there are no data on fetal TH levels from human
pregnancies, where the child (and therefore the placenta) was
affected by a MCT8 mutation. Studies in adult mice have shown
that global Mct8 deletion results in a hypothyroid state in some
organs (brain) and a hyperthyroid state in others (liver, kidney)
[21,22,44], depending on the TH transporters and deiodinases
that are active in each tissue. We have demonstrated the
expression of Mct8 in the mouse placenta. However, our attempts
to quantify transplacental TH transport by Mct8 in mice before
the onset of endogenous fetal TH production have been hindered
by the low levels of T4 and T3 present in E14.5 mouse fetuses.
Furthermore, the finding that D3 activity in the placenta remains
unaltered when Mct8 is absent, suggests that either Mct8 knockout
does not alter intracellular placental TH content or D3 activity
remains unaltered in the face of an altered intracellular TH
concentration. This is similar to reports that placental deiodinase
activity was not affected in human cases of fetal hypothyroidism
[39] and maternal hypothyroidism [45], as well as following in vitro
T3 treatment of human primary cytotrophoblast cells [10].
MCT8 over-expression amplified the pro-invasive effect of T3,
suggesting that MCT8 may play a role in regulating invasion by
promoting T3 transport into EVT and therefore increasing
intracellular T3 availability. However, this effect was modest
and may not be unique to MCT8, and other TH transporters
could have a similar effect. Surprisingly, despite MCT8 silencing
resulting in a 40% reduction in net T3 uptake, SGHPL-4 invasion
was not affected significantly. It is possible that regulators of TH
action, namely other TH transporters, D2, D3 and TRs
compensate for the lack of MCT8. Yet we have found that T3
treatment of SGHPL-4 cells does not affect the expression of these
genes (unpublished data). It is likely that in EVT there are other
more dominant factors involved in the regulation of invasion,
which could attenuate the effects of T3 insufficiency, such as
autocrine and paracrine effects of trophoblast-secreted cytokines
and growth factors. For example, insulin-like growth factor (IGF)-
II has been shown to promote the invasion of EVT-like cells in an
autocrine manner [46]. The lack of impact of MCT8 silencing
upon trophoblast invasion is also reflected by the limited
epidemiological data derived from the relatively few cases of
MCT8 mutations in humans, with approximately 80 families
identified world-wide thus far [47]. There have not yet been any
reports of a preponderance of malplacentation disorders which are
typically associated with impaired EVT invasion, such as IUGR,
pre-eclampsia, preterm delivery and pregnancy loss, which
suggests that compensatory mechanisms may exist in vivo in
human to attenuate the effects of reduced T3 uptake by
trophoblast cells.
There is already evidence that MCT8 regulates cell turnover in
several cell types. Reports of a hyperplastic thyroid lesion in a male
patient carrying an MCT8 mutation and papillary hyperplasia in
Mct8 knockout mice [48] suggest that MCT8 suppresses thyrocyte
cell turnover in vivo. Furthermore, we have previously reported
that MCT8 suppresses the proliferation of JEG-3 (a choriocarci-
noma cell line that is MCT8-null) and N-Tera-2 (a neuronal
precursor cell line) cells [32] in a T3-independent manner, just as
MCT8 decreased the viability of non-proliferating primary term
cytotrophoblast. Interestingly, the EVT-like cell line, SGHPL-4,
was unaffected by changes in MCT8 expression and such a
contrast suggests that MCT8 regulation of cell viability is a cell-
specific effect. Since primary cytotrophoblast do not proliferate in
culture, altered cell viability cannot be accounted for by changes in
cell proliferation or by an activation of the caspase cascade. MCT8
may instead influence parallel pathways that are caspase-
independent leading to increased cell death. How MCT8 affects
cell viability independently of T3 is unknown. Investigations into
the ability of MCT8 to transport compounds other than THs,
have been negative [12,49]. Alternatively, MCT8 may affect cell
viability independently of its transporter function. Regardless of
the mechanism responsible, the adverse effect of MCT8 on the
viability of cytotrophoblast cells is consistent with our hypothesis
that the increased placental expression of MCT8 in IUGR
pregnancies may contribute to the pathophysiology of decreased
placental size and, hence, fetal size [6,23,24].
In mice, we did not observe any significant changes in the
expression of a proliferative marker when we compared whole
placental homogenates from wild-type with that from Mct8
knockout fetuses. Counting the number of cells within the Lz also
revealed no changes in trophoblast (or endothelial) cell number
with Mct8 knockout. Only male conceptuses in mice were studied.
It is currently unclear whether the discrepancy in MCT8 effects
upon cell viability in human trophoblast in vitro and upon
trophoblast cell number in mouse placenta in vivo is due to
compensatory mechanisms that may occur in vivo or due to species
differences. Investigation of placentae from human pregnancies
where the fetus carries a MCT8 mutation would be critical in
answering this question.
Against a uniform maternal genotype (heterozygous female
carriers Mct8+/2) in mice and amongst male conceptuses Mct8
knockout resulted in a 25% reduction in fetal to placental weight
ratio compared to wild-type, which is indicative of reduced
placental efficiency [50]. Placental efficiency is influenced by
environmental conditions during pregnancy, as well as by the
expression of different genes [51,52]. For instance, Phlda2, a
maternally-expressed imprinted gene, is one of the best studied
genes which has been strongly associated with birthweight in
humans. In mice, Phlda2 knockout results in increased placental
weight with no change or a slight decrease in fetal weight and a
23% reduction in the fetal to placental weight ratio in the mutants
compared to wild-type littermates [51], which is comparable to the
magnitude of effect on fetal to placental weight ratio observed in
our Mct8 model. A reduction in fetal to placental weight ratio may
reflect a compensatory mechanism whereby a malfunctioning
placenta enlarges to preserve adequate transplacental transport
and normalize fetal growth. However, stereohistological analysis of
the placenta revealed that the volume fraction of the Lz, which is
responsible for transplacental transport in the mouse, was in fact,
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lower with Mct8 knockout. Therefore, it is unlikely that the
difference in the fetal to placental weight ratio reflects an
adaptation to optimize maternal-fetal exchange. Instead, there
was a general trend of increased volumes of every placental region
with Mct8 knockout suggestive of a generalized increase in
placental cell growth and an opposite trend of reduced fetal
growth at E18.5, which only became significantly different when
expressed as a ratio. This suggests that Mct8 knockout has subtle
and different effects upon placental and fetal growth, and that
differences in fetal to placental weight ratios cannot be explained
by isolated effects on trophoblast cell growth.
Our data demonstrate that MCT8 makes a significant
contribution to TH transport by human placental cells. Further-
more, changes in the expression of MCT8 affect the two major
human trophoblast cell types differently and via both T3-
dependent (invasion) and T3-independent (cell viability) mecha-
nisms. However, findings in Mct8 knockout mice show no
significant differences in placental cell growth although a reduced
fetal to placental weight ratio does suggest subtle effects on overall
fetoplacental growth. It is possible that compensatory mechanisms
exist in vivo that attenuate the effects of Mct8 knockout. However,
we cannot exclude the possibility that Mct8 may have different
effects on human and mouse placental cells.
Supporting Information
Figure S1 Efficiency of MCT8 silencing and over-
expression in the EVT-like cell line, SGHPL-4. A:
Knock-down of endogenous MCT8 mRNA expression in
SGHPL-4 cells was assessed by quantitative RT-PCR. Bars
represent average of six experiments +SEM. The mean expression
in cells treated with control siRNA was given the arbitrary value of
one. Statistically significant differences are indicated by
***P,0.001. B: Changes in overall MCT8 protein expression
following MCT8 silencing were assessed by western blotting.
Whole cell protein lysates (70 mg) of SGHPL-4 cells were probed
with rabbit anti-MCT8 antibody [43] followed by secondary anti-
rabbit antibody conjugated with HRP. The expression of b-actin
was assessed to control for sample loading. C: Representative
experiment showing the percentage of SGHPL-4 cells that were
successfully transfected with HA-tagged MCT8 as assessed by flow
cytometry. The cells were probed with a mouse anti-HA antibody
(1:50; Cell Signalling) followed by a secondary antibody labelled
with green-fluorescent Alexa Fluor 488 dye (1:1,000; Invitrogen).
Cells transfected with vector only (VO) were used as negative
control. D: Changes in overall MCT8 protein expression following
MCT8 over-expression assessed by western blotting.
(TIFF)
Figure S2 Efficiency of MCT8 silencing and over-
expression in primary term cytotrophoblast cells. A:
Knock-down of endogenous MCT8 mRNA expression in
cytotrophoblast cells was assessed by quantitative RT-PCR. Bars
represent average of three experiments +SEM. The mean
expression in cells transfected with control siRNA was given the
arbitrary value of one. Statistically significant differences are
indicated by ***P,0.001. B: Changes in overall MCT8 protein
expression following MCT8 silencing were assessed by western
blotting. Whole cell protein lysates (30 mg) were probed with rabbit
anti-MCT8 antibody [6] followed by secondary anti-rabbit
antibody conjugated with HRP. The expression of b-actin was
assessed to control for sample loading. C: A representative
experiment showing the percentage of cytotrophoblast cells that
were successfully transfected with HA-tagged MCT8 as assessed
by flow cytometry. The cells were probed with anti-HA antibody
followed by secondary antibody labelled with green-fluorescent
Alexa Fluor 488 dye. Cells transfected with vector only (VO) were
used as negative control. D: Changes in overall MCT8 protein
expression following MCT8 over-expression assessed by western
blotting.
(TIFF)
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